Dr. Misaki Wanyengera is a medical doctor with graduate training across Immunology, Vaccinology, Clinical Microbiology, Filovirology and Genetics. He is a member of the African Society for Human Genetics (AFSHG) & inaugural chair of the H3 Consortium’s Education and Coordinated Working Group (ECTWG,2013-2016). In 2017, he was fellow of the U.S. NHGRI’s International Summit in Human Genetics and Genomics.
Dr. Wanyengera completed his Phd 92018) with a thesis titled: Exploration of Mycobacterium Tuberculosis Thyimidylate kinase B cell epitopes are sero-diagnostic and culture biomarkers for rapid and easy detection of Tuberculosis (NIH/Forgarty).His research interests center on Pathogen OMICS, with the goal of identifying new molecular targets for R&D of new diagnostics, therapeutics and vaccines. He is an innovator(filled 3PCTs at URSB, ARIPO and WIPO: Ebola RDT, HIV-1 Gene Therapeutic, and next Gen TB Diagnostics). And Bio-Entrepreneur (Founder & CSO, Start-up: Restrizymes Biotherapeutics “U” LTD)
